Page last updated: 2024-09-05

2'-hydroxyflavanone and Carcinoma, Ductal, Pancreatic

2'-hydroxyflavanone has been researched along with Carcinoma, Ductal, Pancreatic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Li, J; Ma, Q; Qian, W; Wang, Z; Wu, S; Wu, Z; Yue, Y; Zhang, M	1

Other Studies

1 other study(ies) available for 2'-hydroxyflavanone and Carcinoma, Ductal, Pancreatic

Article	Year
2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling. Cancer letters, 2020, 02-28, Volume: 471 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Flavanones; Humans; Mice; Pancreatic Neoplasms; Protein Kinase Inhibitors; Random Allocation; STAT3 Transcription Factor	2020

Article

Year

2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling.

Cancer letters, 2020, 02-28, Volume: 471

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Flavanones; Humans; Mice; Pancreatic Neoplasms; Protein Kinase Inhibitors; Random Allocation; STAT3 Transcription Factor

2020